Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab and BD0801 With or Without Chemotherapy in Advanced Solid Tumors
CTR20212879Phase 2Terminated
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of suvemcitug in Nonhematologic neoplasms, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), sponsored by Simcere Pharmaceutical Group. Started Nov 2021; status: terminated.
02
Drugs
suvemcitug
03
Conditions
Nonhematologic neoplasmshepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20212879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212879.